Table 1.

HCMV vaccines that have undergone evaluation in clinical trials.

CMV Vaccines Evaluated in Clinical Trials
Live, Attenuated Vaccines
AD169 Vaccine	Elicited HCMV-specific antibody responses in seronegative vaccine recipients Significant injection-site and systemic reactogenicity No ongoing studies active
Towne (+/− rhIL12)	Elicits broad-based humoral and cellular immune responses Favorable safety profile; no evidence for latency or viral shedding in recipients Lack of efficacy for HCMV infection; reduced HCMV disease in renal transplant recipients Augmentation of immunogenicity by inclusion of recombinant IL-12 in phase 1 studies
Towne/Toledo Chimera Vaccines	Favorable safety profile; no evidence for latency or viral shedding in recipients Attenuated compared to Toledo strain of HCMV No efficacy data available
Subunit Vaccines
Glycoprotein B/MF59 Adjuvant (CHO Cell Expression)	Favorable safety profile High-titer neutralizing antibody and strong cell- mediated immune responses Efficacy studies ongoing in young women, adolescents, renal transplant patients
Glycoprotein B/Canarypox Vector	Favorable safety profile Suboptimal immunogenicity “Prime-Boost” effect when administered in combination with Towne vaccine
pp65 (U83)/Canarypox Vector	Favorable safety profile Strong antibody and cell-mediated immune responses No efficacy data available
gB/pp65/IE1 Trivalent DNA Vaccine gB/pp65 Bivalent DNA Vaccine	DNA vaccine adjuvanted with poloxamer adjuvant and benzalkonium chloride Phase I studies completed Phase 2 study ongoing with bivalent gB/pp65 vaccine in HSC transplant recipients
gB/pp65/IE1 Alphavirus Replicon Trivalent Vaccine	Engineered using replication-deficient alphavirus technology Generation of virus-like replicon particles (VRPs) Phase 1 clinical trial recently initiated